Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK.

Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK.

Publication date: Jan 22, 2024

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published suspected adverse drug reactions to vaccines against COVID-19. Ocular inflammatory events following COVID-19 vaccination have been reported worldwide. We analysed MHRA data on spontaneous reports of suspected ocular inflammatory events following COVID-19 vaccination between January 2021 and September 2022. The MHRA received 300 UK spontaneous suspected reports of ocular inflammatory events following COVID-19 vaccination, with a calculated prevalence of 6. 6 events per 1 000 000 vaccinated individuals. Anterior uveitis was the most common phenotype (58. 3%), followed by optic neuritis in 39. 3%. Median number of days between vaccination and onset was 8 days. Resolution of the event was seen in 52. 3%. Ocular inflammatory events following COVID-19 vaccination have a very rare prevalence in the UK. There is no increase in the reporting rate of uveitis, optic neuritis and scleritis following COVID-19 vaccination when compared with the range of incidence in the UK population. The Yellow Card System represents a vital instrument within the domain of pharmacovigilance, empowering patients and healthcare professionals to contribute to the ongoing monitoring of medication safety.

Concepts Keywords
Covid Covid-19
Pharmacovigilance
Vaccines

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination
disease MESH adverse drug reactions
disease VO regulatory agency
disease VO vaccinated
disease MESH Anterior uveitis
disease MESH optic neuritis
disease MESH uveitis
disease MESH scleritis
disease VO population

Original Article

(Visited 1 times, 1 visits today)